Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 4.75B +140.3% |
| Revenue (ttm) | 274.48M +51.2% |
| Net Income | 153.56M |
| EPS | 7.50 |
| Shares Out | 20.04M |
| PE Ratio | 31.60 |
| Forward PE | 44.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,942 |
| Open | 235.75 |
| Previous Close | 235.91 |
| Day's Range | 235.65 - 240.53 |
| 52-Week Range | 102.50 - 247.38 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 277.60 (+17.13%) |
| Earnings Date | May 7, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $277.6, which is an increase of 17.13% from the latest price.
News
Ligand to Participate in June Investor Conferences
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% royalty revenue and 23% adjusted EPS growth year-over-year, driven by portfolio expansion and the strategic shift to royalty aggregation. The XOMA Royalty acquisition is expected to be immediately accretive, further diversifying assets and accelerating long-term growth.
Ligand Pharmaceuticals Earnings release: Q1 2026
Ligand Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q1 2026
Ligand Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ligand Pharmaceuticals Quarterly report: Q1 2026
Ligand Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ligand Reports First Quarter 2026 Financial Results
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution ...
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Ligand Pharmaceuticals Transcript: M&A announcement
The acquisition of XOMA Royalty will double the portfolio size, add seven commercial royalties, and over 100 development-stage programs, driving immediate and long-term earnings growth. The all-cash deal is expected to be accretive from 2026, with significant synergies and no shareholder dilution.
Ligand Pharmaceuticals Press release: M&A announcement
Ligand Pharmaceuticals issued a press release on April 27, 2026, disclosing material business information to investors.
Ligand Pharmaceuticals Slides: M&A announcement
Ligand Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deli...
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., ...
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown...
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...
Ligand Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 48% royalty revenue growth and 42% adjusted EPS increase, driven by strong commercial launches and portfolio expansion. 2026 guidance projects continued double-digit growth, supported by a robust late-stage pipeline and over $1B in deployable capital.